Agios Pharmaceuticals, Inc.
37.00USD
-0.1900 (-0.51%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on AGIO.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 45 | 21 | 20 | 13 | 12 | 9 | 11 | 9 |
| Cost of Revenue | 3 | 1 | 2 | 2 | 2 | 1 | 1 | 1 |
| Gross Profit | 42 | 19 | 18 | 11 | 11 | 8 | 9 | 8 |
| Operating Income | -111 | -110 | -122 | -117 | -127 | -107 | -125 | -103 |
| Net Income | -101 | -99 | -108 | -103 | -112 | -89 | -97 | 948 |
| EPS (Diluted) | -$1.69 | -$1.69 | -$1.85 | -$1.78 | -$1.93 | -$1.55 | -$1.74 | $16.22 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)